NEW YORK ( TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Friday's session.

Labopharm ( DDSS) was indicated to trade sharply lower Friday after the specialty pharmaceutical company said it has commenced an offering of up to $20 million of units, which each unit consisting of one common share and a warrant to purchase a portion of a common share. The 50-day average daily volume for Labopharm is 1.72 million, according to the Nasdaq. Shares closed Thursday at $2.01 and were down more than 15% in the after-market session.

China Direct Industries ( CDII) should also trade lower after the Chinese basic materials and consulting company posted an adjusted first-quarter loss of 3 cents a share as revenue dropped 43% from a year ago to $22.3 million. Looking ahead to the full-year, China Direct said it continues to see its net income ranging between $8 million and $10 million on revenue ranging from between $130 million and $150 million. The 50-day average daily volume for China Direct is 1.27 million. The stock finished Thursday at $1.74 before slipping 3.5% in late trading.

Rainmaker Systems ( RMKR) was also poised to lose ground after the sales and marketing software company offered weak guidance for 2010 as it has been notified by Oracle ( ORCL) that some of the programs it currently performs for Sun Microsystems will not be continued past Feb. 28. These programs accounted for approximately 13% of Rainmaker's fiscal 2009 annual revenue and 21% of fourth-quarter revenue. The 50-day average daily volume for Rainmaker is 23,000. Shares closed Thursday at $1.56 and fell nearly 15% in the after-market session.

NeoStem ( NBS) is also poised to fall during Friday's session after the stem cell collection company priced a 5 million common stock offering at $1.35 a share, which is below Thursday's closing price of $1.62 a share. The three-month average daily volume for NeoStem is 70,000, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Check out all of Friday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

If you liked this article you might like

Biotech Stock Mailbag: Vical

Biotech Stock Mailbag: Vical

Biotech Stock Mailbag: Exact Sciences

Biotech Stock Mailbag: Exact Sciences

Biotech Stock Mailbag: Immunomedics

Biotech Stock Mailbag: Immunomedics

Biotech Stock Mailbag: Labopharm

Biotech Stock Mailbag: Labopharm